These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 10398314)

  • 1. Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: case reports, review of the literature and implications for therapy.
    Jubelirer SJ; Koenig BA; Bates MC
    Am J Hematol; 1999 Jul; 61(3):205-8. PubMed ID: 10398314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy.
    Berkowitz SD; Harrington RA; Rund MM; Tcheng JE
    Circulation; 1997 Feb; 95(4):809-13. PubMed ID: 9054735
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute profound thrombocytopenia following abciximab therapy.
    Bishara AI; Hagmeyer KO
    Ann Pharmacother; 2000; 34(7-8):924-30. PubMed ID: 10928405
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute profound thrombocytopenia without bleeding complications after re-administration of abciximab.
    Nguyen N; Salib H; Mascarenhas DA
    J Invasive Cardiol; 2001 Jan; 13(1):56-8. PubMed ID: 11146690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group.
    Berkowitz SD; Sane DC; Sigmon KN; Shavender JH; Harrington RA; Tcheng JE; Topol EJ; Califf RM
    J Am Coll Cardiol; 1998 Aug; 32(2):311-9. PubMed ID: 9708455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Acute profound thrombocytopenia after abciximab therapy during coronary angioplasty.
    Joseph T; Marco J; Gregorini L
    Clin Cardiol; 1998 Nov; 21(11):851-2. PubMed ID: 9825202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute profound thrombocytopenia without bleeding complications after abciximab administration.
    Elmi F; Oza R; Mascarenhas DA
    J Invasive Cardiol; 1999 May; 11(5):313-5. PubMed ID: 10745539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy.
    Sane DC; Damaraju LV; Topol EJ; Cabot CF; Mascelli MA; Harrington RA; Simoons ML; Califf RM
    J Am Coll Cardiol; 2000 Jul; 36(1):75-83. PubMed ID: 10898416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty.
    EPIC Investigators
    N Engl J Med; 1994 Apr; 330(14):956-61. PubMed ID: 8121459
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombocytopenia associated with c7E3 Fab (abciximab).
    Schell DA; Ganti AK; Levitt R; Potti A
    Ann Hematol; 2002 Feb; 81(2):76-9. PubMed ID: 11907786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, eptifibatide and abciximab: outcomes, complications and thrombocytopenia during percutaneous coronary intervention.
    Suleiman M; Gruberg L; Hammerman H; Aronson D; Halabi M; Goldberg A; Grenadier E; Boulus M; Markiewicz W; Beyar R
    J Invasive Cardiol; 2003 Jun; 15(6):319-23. PubMed ID: 12777670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade.
    Kereiakes DJ; Berkowitz SD; Lincoff AM; Tcheng JE; Wolski K; Achenbach R; Melsheimer R; Anderson K; Califf RM; Topol EJ
    Am Heart J; 2000 Jul; 140(1):74-80. PubMed ID: 10874266
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abciximab-induced acute profound thrombocytopenia postpercutaneous coronary intervention.
    Golden T; Ghazala S; Wadeea R; Junna S
    BMJ Case Rep; 2017 Jul; 2017():. PubMed ID: 28710245
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
    Lincoff AM; Tcheng JE; Califf RM; Bass T; Popma JJ; Teirstein PS; Kleiman NS; Hattel LJ; Anderson HV; Ferguson JJ; Cabot CF; Anderson KM; Berdan LG; Musco MH; Weisman HF; Topol EJ
    Am J Cardiol; 1997 Feb; 79(3):286-91. PubMed ID: 9036746
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The importance of differentiating ReoPro (c7E3 abciximab) induced thrombocytopenia from heparin-induced thrombocytopenia.
    Davidson SJ; Turner N; Clague JR; Oldershaw PJ; Burman JF
    Thromb Haemost; 1999 Nov; 82(5):1560-1. PubMed ID: 10595660
    [No Abstract]   [Full Text] [Related]  

  • 18. Successful use of eptifibatide as an adjunct to coronary stenting in a patient with abciximab-associated acute profound thrombocytopenia.
    Rao J; Mascarenhas DA
    J Invasive Cardiol; 2001 Jun; 13(6):471-3. PubMed ID: 11385174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Profound thrombocytopenia after abciximab administration in acute myocardial infarction and stent thrombosis following thrombocytopenia remission--a case report].
    Elikowski W; Rzeźniczak J; Słomczyński M; Psuja P
    Kardiol Pol; 2005 Jan; 62(1):44-7; discussion 48. PubMed ID: 15815778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.